scholarly journals Comment on: Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

2017 ◽  
pp. dkw538
Author(s):  
Spinello Antinori ◽  
Francesca Binda ◽  
Lorena van den Bogaart ◽  
Roberto Rech ◽  
Antonio Castelli ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplant ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Cell Transplant ◽  
Haematological Malignancies ◽  
Transplant Recipients

scholarly journals Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

2016 ◽  
Vol 71 (9) ◽  
pp. 2379-2385 ◽  
Author(s):  
Catherine Cordonnier ◽  
Simone Cesaro ◽  
Georg Maschmeyer ◽  
Hermann Einsele ◽  
J. Peter Donnelly ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplant ◽  
Laboratory Diagnosis ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Cell Transplant ◽  
Haematological Malignancies ◽  
Transplant Recipients ◽  
Allogeneic Hsct ◽  
Prevention And Treatment

The risk of patients with ALL and recipients of an allogeneic HSCT developing Pneumocystis jirovecii pneumonia is sufficiently high to warrant guidelines for the laboratory diagnosis, prevention and treatment of the disease. In this issue, the European Conference on Infections in Leukemia (ECIL) presents its recommendations in three companion papers.

scholarly journals Comment on:Pneumocystis jiroveciipneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

2016 ◽  
pp. dkw460 ◽  
Author(s):  
Spinello Antinori ◽  
Francesca Binda ◽  
Lorena van den Bogaart ◽  
Roberto Rech ◽  
Antonio Castelli ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Haematological Malignancies ◽  
Transplant Recipients

scholarly journals ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

2016 ◽  
Vol 71 (9) ◽  
pp. 2397-2404 ◽  
Author(s):  
Johan Maertens ◽  
Simone Cesaro ◽  
Georg Maschmeyer ◽  
Hermann Einsele ◽  
J. Peter Donnelly ◽  
...  
Keyword(s):  
Stem Cell Transplant ◽  
Primary Prophylaxis ◽  
Pneumocystis Jirovecii ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Evidence Based ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Allogeneic Hsct ◽  
Drug Of Choice ◽  
Immune Deficiencies

AbstractThe 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2–3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults (A-II) and children (A-I) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen (B-II). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

Sign in / Sign up

Export Citation Format

Share Document